Altair Nanotechnologies signs agreement with Lilly
Altair Nanotechnologies Inc. has entered into
a commercial research agreement with the Elanco Animal Health Division of Eli
Lilly and Company. The agreement provides Elanco with exclusive rights to
develop animal health products using Altairnano's nanotechnology-based
The agreement provides a schedule for expedient progress from development and
proof of concept to readying products for clinical trials and regulatory
Altairnano is an innovator and supplier of advanced ceramic
nanomaterials. The company focuses on nanotechnology applications to enable new
potentially high-growth markets.
In alternative energy, Altairnano is
pioneering new battery materials and systems. The company is applying
nanotechnology to the development of drug candidates for humans and companion
animals, coatings materials for implants, and materials for dental
Its high performance nanomaterials have applications in
paints, coatings, and the treatment of water and air.
Elanco is a
global research-based animal health company that develops and markets products
to improve the health and production of animals in more than 100 countries.
Elanco is a division of Eli Lilly and Company, a leading innovation-driven
pharmaceutical corporation. Elanco products enhance animal health, wellness,
welfare and performance.
To comment, login here
Or register to be able to comment.